Maze Therapeutics (MAZE) Profit After Tax (2024 - 2026)
Maze Therapeutics (MAZE) posted Profit After Tax of -$24.2 million for Q1 2026, up 29.97% sequentially from -$34.6 million in Q4 2025, and up 26.16% YoY from -$19.2 million in Q1 2025.
Maze Therapeutics (MAZE) Profit After Tax (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Profit After Tax for 3 years, with the latest figure at -$24.2 million in Q1 2026.
- Quarterly Profit After Tax rose 26.16% year-over-year to -$24.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$122.5 million (down 261.47% YoY) and the FY2025 annual result came in at -$131.1 million, down 3950.81% from the prior year.
- Profit After Tax climbed to -$24.2 million in Q1 2026 per MAZE's latest filing, from -$34.6 million in the prior quarter.
- Over five years, Profit After Tax peaked at $139.1 million in Q2 2024 and troughed at -$34.6 million in Q4 2025.
- A 3-year average of -$8.8 million and a median of -$30.1 million in 2025 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2025 and 2026: Profit After Tax slumped 514.43% in 2025, then advanced 26.16% in 2026.
- Over 3 years, Profit After Tax stood at -$5.6 million in 2024, then plunged by 514.43% to -$34.6 million in 2025, then gained by 29.97% to -$24.2 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$24.2 million, -$34.6 million, and -$30.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | -44.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.73 Mn |
| Mar 31, 2026 | -24.21 Mn |
| Dec 31, 2025 | -34.57 Mn |
| Sep 30, 2025 | -30.09 Mn |
| Jun 30, 2025 | -33.68 Mn |
| Mar 31, 2025 | -32.79 Mn |
| Dec 31, 2024 | -5.63 Mn |
| Sep 30, 2024 | -24.75 Mn |
| Jun 30, 2024 | 139.06 Mn |
| Mar 31, 2024 | -32.49 Mn |